Tectonic Therapeutic Inc reported its fourth quarter and full-year 2025 financial results, detailing revenue, R&D spending and recent operational milestones as it advances its targeted protein degradation drug pipeline.
For the full year, the company recorded revenues of $65.2 million, compared with $71.8 million in 2024, reflecting continued partnerships and milestone receipts, according to the financial update. R&D expenses increased to $96.3 million from $82.5 million, driven by ongoing clinical activities and preclinical research, while general and administrative costs were largely stable year over year. The company ended the year with $158.9 million in cash, cash equivalents and marketable securities, which Tectonic says is expected to support operations into the second half of 2027.
Tectonic highlighted clinical and discovery progress across its pipeline, including preparations for a late-stage study of its targeted protein degrader TTX-030 in oncology and ongoing early-stage programs in central nervous system disorders. The company also noted expansion of its degrader platform and strategic collaborations focused on advancing novel therapeutic modalities.
Additionally, Tectonic’s business update mentioned progress toward IND filings for earlier-stage degrader candidates and investments in manufacturing and translational research capabilities to support future clinical execution, the company states. The firm said it is prioritising programmes with near-term data catalysts expected through 2026.
The reported financial results and operational highlights reflect Tectonic’s continued focus on building its targeted protein degradation portfolio and advancing clinical programs aimed at high-unmet-need diseases. Revenue and expense trends illustrate ongoing investment in innovation and pipeline expansion as the company positions itself for upcoming development milestones.
